Here are the 424B prospectus supplements from Climb Bio, Inc. (CLYM) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CLYM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLYM filings page.
Climb Bio, Inc. entered into a Sales Agreement with Jefferies LLC to sell, from time to time, up to $100,000,000 of its common stock in an at‑the‑market offering on the Nasdaq Global Market under the symbol CLYM. The sales agent commission is up to 3.0% of gross sales. The prospectus supplement states the last reported sale price was $10.91 per share on June 11, 2026, and that there were 47,768,543 shares outstanding as of March 31, 2026. Net proceeds, if any, will be used for general corporate purposes, including working capital, R&D, clinical development, and potential acquisitions.
Climb Bio, Inc. is registering the resale of up to 11,587,000 shares of its common stock for selling stockholders. This prospectus covers resale from time to time of 11,587,000 shares (9,481,000 outstanding shares and 2,106,000 shares issuable upon exercise of prefunded warrants) on behalf of the selling stockholders. The sales are resales by the selling stockholders; the company states it will not receive proceeds from resales, except that it will receive cash if the prefunded warrants are exercised for shares. The registration was filed to satisfy registration rights granted in connection with a private placement and includes a Beneficial Ownership Limitation of 33.0% that restricts exercise of the prefunded warrants. Shares outstanding were 57,263,023 as of May 14, 2026.